A novel treatment for tinnitus, a condition affecting millions worldwide, is demonstrating significant success in reducing or eliminating the persistent ringing, buzzing, or roaring sounds in the ears. The device, named Lenire, utilizes a dual-stimulus approach combining auditory and physical stimulation to retrain the brain.
Globally, an estimated 750 million people suffer from tinnitus, with millions more in the United States experiencing this often debilitating condition. For many, tinnitus is a chronic issue linked to age-related hearing loss or noise damage, significantly impacting sleep and mental well-being. While current treatments often focus on managing symptoms through therapies like cognitive behavioral therapy or sound-masking devices, Lenire aims to offer a more direct, long-term solution.
The Lenire device works by delivering soothing sounds through headphones while simultaneously stimulating the trigeminal nerve in the head via a small device placed on the tongue. Researchers hypothesize that this paired stimulation can help the brain to ignore the internal sounds of tinnitus. Recommended usage involves two 30-minute sessions daily for approximately 12 weeks, though patients may continue use as needed.
Clinical trials and real-world studies have indicated a high efficacy rate for the Lenire device. A 2022 clinical trial involving 450 participants reported that 90 percent experienced symptom reduction over six weeks, with results sustained a year later. More recent studies have shown even higher success rates. A real-world study of 140 tinnitus sufferers published in the American Journal of Audiology found that over 80 percent saw significant improvement after 12 weeks. In a 2025 study of 212 individuals with moderate to severe tinnitus in Alaska, 91.5 percent reported significant improvement after 12 weeks of treatment, with the proportion experiencing severe or catastrophic tinnitus dropping from roughly 50 percent to 11 percent.
Experts suggest that the device may be particularly effective for individuals with more severe tinnitus, potentially because these patients are more motivated and less responsive to traditional therapies. The device is not suitable for all individuals, however. Contraindications include certain implants like pacemakers or cochlear implants, and potential users with oral infections, head and neck pain, or a history of fainting require further medical assessment.
While effective, the Lenire device comes with a significant cost, approximately $4,000 in the U.S., and is not typically covered by standard insurance or Medicare. This cost factor, coupled with the need for professional assessment by an audiologist, presents a barrier for some seeking relief.
Tinnitus cases have reportedly risen by 50 percent in the past two decades, with contributing factors including an aging population, increased stress, and widespread use of headphones at high volumes, particularly among younger generations. The growing prevalence underscores the need for effective treatment options like Lenire.